AB
KROS icon

Amalgamated Bank’s Keros Therapeutics KROS Stock Holding History

Amalgamated Bank’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-918
Closed -$19K – 2255
2025
Q4 		$19K Sell
918
-140
-13% -$2.46K ﹤0.01% 2131
2025
Q3 		$17K Hold
1,058
– – ﹤0.01% 2201
2025
Q2 		$14K Hold
1,058
– – ﹤0.01% 2274
2025
Q1 		$11K Buy
1,058
+157
+17% +$1.82K ﹤0.01% 2322
2024
Q4 		$14K Hold
901
– – ﹤0.01% 2275
2024
Q3 		$52K Hold
901
– – ﹤0.01% 1836
2024
Q2 		$41K Buy
901
+34
+4% +$1.83K ﹤0.01% 1900
2024
Q1 		$57K Sell
867
-2,255
-72% -$134K ﹤0.01% 1834
2023
Q4 		$124K Sell
3,122
-207
-6% -$6.49K ﹤0.01% 1935
2023
Q3 		$106K Hold
3,329
– – ﹤0.01% 1974
2023
Q2 		$134K Buy
3,329
+645
+24% +$28.3K ﹤0.01% 1968
2023
Q1 		$115K Sell
2,684
-561
-17% -$28.3K ﹤0.01% 2000
2022
Q4 		$156K Buy
3,245
+439
+16% +$20.5K ﹤0.01% 1948
2022
Q3 		$106K Buy
2,806
+171
+6% +$5.93K ﹤0.01% 2124
2022
Q2 		$73K Buy
2,635
+93
+4% +$4.08K ﹤0.01% 2307
2022
Q1 		$138K Buy
+2,542
New +$130K ﹤0.01% 2078

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Amalgamated Bank's KROS Position: Q1 2026 in Review

Amalgamated Bank sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 918 shares — an estimated $19K sold.

Amalgamated Bank first reported a position in KROS in Q1 2022 and held it in 16 quarters. The position peaked at $156K in Q4 2022. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Amalgamated Bank reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 918 Keros Therapeutics shares in Q1 2026, an estimated $19K.
  • Amalgamated Bank first reported a position in Keros Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Keros Therapeutics position peaked at $156K in Q4 2022.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.